|
Steven Halladay most recently served as Vice President, Clinical and Regulatory Affairs of Durect Corporation, a specialty pharmaceutical company where he was responsible for all regulatory, pre-clinical and clinical activity. Prior to joining Durect, Dr. Halladay served as Senior Executive Vice President of Clingenix, Inc., a clinical research and pharmacogenomics company, and as President and Chief Executive Officer of its wholly-owned subsidiary, Research Services, Inc. Earlier in his career Dr. Halladay spent over a decade with Syntex in roles of increasing responsibility in both the pre-clinical and clinical departments. Dr. Halladay has planned, conducted, analyzed, and reported over 100 clinical trials for FDA and Ex US submissions, Rx and OTC and is considered an expert in the acceleration of clinical development through various strategies. | 